Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016150899 - ANTI-CEACAM6 ANTIBODIES AND USES THEREOF

Publication Number WO/2016/150899
Publication Date 29.09.2016
International Application No. PCT/EP2016/056104
International Filing Date 21.03.2016
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2803
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applicants
  • BAYER PHARMA AKTIENGESELLSCHAFT [DE]/[DE]
Inventors
  • WILLUDA, Jörg
  • TRAUTWEIN, Mark
  • GRITZAN, Uwe
  • FREIBERG, Christoph
  • DITTMER, Frank
  • SCHÖNFELD, Dorian
  • GLÜCK, Julian, Marius
  • PINKERT, Jessica
  • GUTIERREZ, Eva-Maria
  • GOLFIER, Sven
  • HOLTON, Simon
  • BECKHOVE, Philip
  • GE, Yingzi
Agents
  • BIP PATENTS
Priority Data
15160292.723.03.2015EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CEACAM6 ANTIBODIES AND USES THEREOF
(FR) ANTICORPS ANTI-CEACAM6 ET LEURS UTILISATIONS
Abstract
(EN)
The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The disclosure further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
(FR)
Cette invention concerne des régions recombinées se liant à l'antigène et des anticorps et fragments fonctionnels contenant lesdites régions se liant à l'antigène qui sont spécifiques du CEACAM6 humain et du Macaca fascicularis (molécule 6 d'adhérence cellulaire liée à l'antigène carcino-embryonnaire, CD66c, antigène non spécifique à réaction croisée, NCA, NCA-50/90), et qui ne sont pas sensiblement en réaction croisée avec le CEACAM1 humain, le CEACAM3 humain, et le CEACAM5 humain étroitement apparentés. L'invention concerne en outre des procédés permettant de générer ce type d'anticorps. Les anticorps peuvent, par conséquent, être utilisés pour traiter le cancer et autres troubles et affections qui sont associés à l'expression du CEACAM6. Des séquences d'acide nucléique codant pour les anticorps précités, des vecteurs les contenant, des compositions pharmaceutiques et des kits accompagnés d'instructions d'utilisation sont en outre décrits.
Latest bibliographic data on file with the International Bureau